Candriam Eqs L Biotech C USD Cap

Analyst Report
Morningstar's Take
|07/03/2025

by Jeffrey Schumacher
On 30 January 2023, Candriam announced that Naïm Abou-Jaoudé, the firm’s CEO of 16 years, has been tapped to become the CEO of parent company New York Life Investment Management, as of 1 May 2023. He will also take up the position of chair of the board of directors at Candriam in his new role. Vincent Hamelink, current CIO of Candriam, has been selected to take over the reins as CEO, in line with the firm’s historical practice of promoting internally. Hamelink has been in CIO positions here since 2009 and was instrumental in rationalising the firm’s historically large fund lineup and overseeing its traditional investment range. He will be supported by Renato Guerriero, Candriam’s chief sales and distribution officer, in a new role as deputy CEO. Guerriero will also retain his current responsibilities as head of sales. Candriam is still in the process of selecting a new CIO to succeed Hamelink in due course.

Abou-Jaoudé, Hamelink, and Guerriero have worked together for almost 20 years, bringing stability and continuity to the firm. Abou-Jaoudé will remain close to Candriam for one year to ensure a smooth transition of leadership. In the interim, we will continue to monitor the firm for the pending announcement of its new CIO. We retain the Parent Pillar rating of Average and are not making any changes to the Morningstar Analyst Ratings of covered strategies.

 
A well-designed and effectively executed succession plan provides clarity about the team structure and inspires confidence, earning the strategy an upgrade of the People Pillar Rating from Average to Above Average. The Process Pillar Rating is maintained at Above Average.

Morningstar has enhanced the way we assess alpha opportunity for funds, which is a key component in our Morningstar Medalist Rating calculation. More of this strategy's Medalist Ratings than usual may therefore change with this update even in the absence of changes to pillar ratings or fund costs.

After more than 24 years at the helm, seasoned biotechnology expert Rudi van den Eynde announced his upcoming retirement in February 2024. An effective succession plan was put in place to ensure a smooth transition into new leadership. In February 2024, Linden Thomson joined Candriam as lead portfolio manager for the biotechnology strategy and comanager of the oncology strategy, bringing two decades of sector expertise. She maintains a data-driven approach while sensibly refining the investment process and portfolio. Servaas Michielssens rejoined Candriam the same month to lead the healthcare team and comanage Candriam Life Care, while rejoining the biotechnology strategy in May as a comanager. Previously part of the team from 2016 to 2022, his familiarity with the strategy provides continuity. Van den Eynde remained involved until his January 2025 retirement. Supported by four analysts, the well-resourced team collaborates effectively across Candriam’s healthcare strategies.

The strategy follows a solid investment philosophy with a well-structured, proven process, thoughtfully refined under Thomson. It emphasizes rigorous bottom-up research, clinical data analysis, and continuous company monitoring, integrating scientific insights and industry interactions to assess market potential. Thomson has enhanced the process by emphasizing management quality and improving documentation of investment rationales. The team identifies high-potential clinical-stage and commercial opportunities using various valuation techniques.

Under Van den Eynde, the fund evolved from a concentrated mid-cap portfolio to a diversified all-cap strategy with around 100 holdings. Since taking over, Thomson has streamlined the portfolio to roughly 75 stocks, reducing smaller high-risk positions and increasing minimum position sizes. With solid risk management, it remains one of the most diversified portfolios in its category, carefully managing exposure across therapeutic areas.

Thomson and Michielssens are well-equipped to sustain the strategy’s stock-picking effectiveness while maintaining its performance characteristics. The strategy typically lags during speculative rallies but demonstrates resilience in downturns. Despite the portfolio refinements, it should perform consistently through market cycles. The team’s strong start in 2024 is encouraging.
 
Morningstar Medalist Rating™A successful transition marks the start of a new era for the strategy.
To find out how Morningstar rates a fund click here.
Morningstar Pillars
PeopleAbove Average
ParentAverage
ProcessAbove Average
 
Morningstar Medalist RatingMorningstar assigns the Medalist Rating to funds that are qualitatively and quantitatively assessed through manager research and algorithmic processes. The assessment turns on three key “pillars” – People, Process, and Parent – that yield an estimate of how well a fund will perform before fees but after adjusting for risk.
Permissions/Reprints   E-mail Morningstar     
A fim de prover consistência para todos os relatórios fornecidos por diferentes Asset Managers, os data points calculados apresentados são gerados usando uma metodologia de cálculo proprietária da Morningstar, que pode ser conferida com mais detalhes em(https://www.morningstar.com/research/signature)
© Copyright 2025 Morningstar, Inc. Todos os direitos reservados.

Termos de Uso        Política Privacidade        Cookie Settings        Divulgações